1
|
Pérez‐Carretero C, Hernández‐Sánchez M, González T, Quijada‐Álamo M, Martín‐Izquierdo M, Santos‐Mínguez S, Miguel‐García C, Vidal M, García‐De‐Coca A, Galende J, Pardal E, Aguilar C, Vargas‐Pabón M, Dávila J, Gascón‐Y‐Marín I, Hernández‐Rivas J, Benito R, Hernández‐Rivas J, Rodríguez‐Vicente A. TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. Am J Hematol 2022; 97:903-914. [PMID: 35472012 DOI: 10.1002/ajh.26578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 04/11/2022] [Accepted: 04/17/2022] [Indexed: 11/08/2022]
Abstract
Interstitial 14q32 deletions involving IGH gene are infrequent events in chronic lymphocytic leukemia (CLL), affecting less than 5% of patients. To date, little is known about their clinical impact and molecular underpinnings, and its mutational landscape is currently unknown. In this work, a total of 871 CLLs were tested for the IGH break-apart probe, and 54 (6.2%) had a 300 kb deletion of 3'IGH (del-3'IGH CLLs), which contributed to a shorter time to first treatment (TFT). The mutational analysis by next-generation sequencing of 317 untreated CLLs (54 del-3'IGH and 263 as the control group) showed high mutational frequencies of NOTCH1 (30%), ATM (20%), genes involved in the RAS signaling pathway (BRAF, KRAS, NRAS, and MAP2K1) (15%), and TRAF3 (13%) within del-3'IGH CLLs. Notably, the incidence of TRAF3 mutations was significantly higher in del-3'IGH CLLs than in the control group (p < .001). Copy number analysis also revealed that TRAF3 loss was highly enriched in CLLs with 14q deletion (p < .001), indicating a complete biallelic inactivation of this gene through deletion and mutation. Interestingly, the presence of mutations in the aforementioned genes negatively refined the prognosis of del-3'IGH CLLs in terms of overall survival (NOTCH1, ATM, and RAS signaling pathway genes) and TFT (TRAF3). Furthermore, TRAF3 biallelic inactivation constituted an independent risk factor for TFT in the entire CLL cohort. Altogether, our work demonstrates the distinct genetic landscape of del-3'IGH CLL with multiple molecular pathways affected, characterized by a TRAF3 biallelic inactivation that contributes to a marked poor outcome in this subgroup of patients.
Collapse
Affiliation(s)
- Claudia Pérez‐Carretero
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| | - María Hernández‐Sánchez
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| | - Teresa González
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| | - Miguel Quijada‐Álamo
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| | - Marta Martín‐Izquierdo
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| | - Sandra Santos‐Mínguez
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| | - Cristina Miguel‐García
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| | | | | | | | - Emilia Pardal
- Servicio de Hematología Hospital Virgen del Puerto Plasencia Spain
| | - Carlos Aguilar
- Servicio de Hematología, Complejo Hospitalario de Soria Soria Spain
| | | | - Julio Dávila
- Servicio de Hematología Hospital Nuestra Señora de Sonsoles Ávila Spain
| | - Isabel Gascón‐Y‐Marín
- Servicio de Hematología, Hospital Universitario Infanta Leonor Universidad Complutense Madrid Spain
| | | | - Rocío Benito
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| | - Jesús‐María Hernández‐Rivas
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| | - Ana‐Eugenia Rodríguez‐Vicente
- Universidad de Salamanca, IBSAL, IBMCC‐ Centro de Investigación del Cáncer (USAL‐CSIC) Salamanca Spain
- Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain
| |
Collapse
|
2
|
Quijada‐Álamo M, Pérez‐Carretero C, Hernández‐Sánchez M, Rodríguez‐Vicente A, Herrero A, Hernández‐Sánchez J, Martín‐Izquierdo M, Santos‐Mínguez S, del Rey M, González T, Rubio‐Martínez A, García de Coca A, Dávila‐Valls J, Hernández‐Rivas J, Parker H, Strefford JC, Benito R, Ordóñez J, Hernández‐Rivas J. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia. Clin Transl Med 2021; 11:e304. [PMID: 33634999 PMCID: PMC7862176 DOI: 10.1002/ctm2.304] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Revised: 01/13/2021] [Accepted: 01/18/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Several genetic alterations have been identified as driver events in chronic lymphocytic leukemia (CLL) pathogenesis and oncogenic evolution. Concurrent driver alterations usually coexist within the same tumoral clone, but how the cooperation of multiple genomic abnormalities contributes to disease progression remains poorly understood. Specifically, the biological and clinical consequences of concurrent high-risk alterations such as del(11q)/ATM-mutations and del(17p)/TP53-mutations have not been established. METHODS We integrated next-generation sequencing (NGS) and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 techniques to characterize the in vitro and in vivo effects of concurrent monoallelic or biallelic ATM and/or TP53 alterations in CLL prognosis, clonal evolution, and therapy response. RESULTS Targeted sequencing analysis of the co-occurrence of high-risk alterations in 271 CLLs revealed that biallelic inactivation of both ATM and TP53 was mutually exclusive, whereas monoallelic del(11q) and TP53 alterations significantly co-occurred in a subset of CLL patients with a highly adverse clinical outcome. We determined the biological effects of combined del(11q), ATM and/or TP53 mutations in CRISPR/Cas9-edited CLL cell lines. Our results showed that the combination of monoallelic del(11q) and TP53 mutations in CLL cells led to a clonal advantage in vitro and in in vivo clonal competition experiments, whereas CLL cells harboring biallelic ATM and TP53 loss failed to compete in in vivo xenotransplants. Furthermore, we demonstrated that CLL cell lines harboring del(11q) and TP53 mutations show only partial responses to B cell receptor signaling inhibitors, but may potentially benefit from ATR inhibition. CONCLUSIONS Our work highlights that combined monoallelic del(11q) and TP53 alterations coordinately contribute to clonal advantage and shorter overall survival in CLL.
Collapse
Affiliation(s)
- Miguel Quijada‐Álamo
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - Claudia Pérez‐Carretero
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - María Hernández‐Sánchez
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
- Department of Medical OncologyDana‐Farber Cancer InstituteBostonMassachusettsUSA
- Broad Institute of Harvard and MITCambridgeMassachusettsUSA
| | - Ana‐Eugenia Rodríguez‐Vicente
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - Ana‐Belén Herrero
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - Jesús‐María Hernández‐Sánchez
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - Marta Martín‐Izquierdo
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - Sandra Santos‐Mínguez
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - Mónica del Rey
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - Teresa González
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | | | | | | | | | - Helen Parker
- School of Cancer SciencesFaculty of MedicineUniversity of SouthamptonSouthamptonUK
| | | | - Rocío Benito
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - José‐Luis Ordóñez
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
| | - Jesús‐María Hernández‐Rivas
- Cancer Research CenterUniversity of Salamanca, IBSAL, IBMCC, CSICSalamancaSpain
- Department of HematologyUniversity Hospital of SalamancaSalamancaSpain
- Department of MedicineUniversity of SalamancaSalamancaSpain
| |
Collapse
|
3
|
Ribera J, Zamora L, Morgades M, Vives S, Granada I, Montesinos P, Gómez‐Seguí I, Mercadal S, Guàrdia R, Nomdedeu J, Pratcorona M, Tormo M, Martínez‐Lopez J, Hernández‐Rivas J, Ciudad J, Orfao A, González‐Campos J, Barba P, Escoda L, Esteve J, Genescà E, Solé F, Feliu E, Ribera J. Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 2019; 58:815-819. [DOI: 10.1002/gcc.22788] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 06/07/2019] [Accepted: 06/13/2019] [Indexed: 12/12/2022] Open
Affiliation(s)
- Jordi Ribera
- Institut de Recerca Contra la Leucemia Josep Carreras, Hospital Germans Trias i PujolUniversitat Autònoma de Barcelona, Institut Català d'Oncologia, Hospital Germans Trias i Pujol Barcelona Spain
| | - Lurdes Zamora
- Institut de Recerca Contra la Leucemia Josep Carreras, Hospital Germans Trias i PujolUniversitat Autònoma de Barcelona, Institut Català d'Oncologia, Hospital Germans Trias i Pujol Barcelona Spain
| | - Mireia Morgades
- Institut de Recerca Contra la Leucemia Josep Carreras, Hospital Germans Trias i PujolUniversitat Autònoma de Barcelona, Institut Català d'Oncologia, Hospital Germans Trias i Pujol Barcelona Spain
| | - Susana Vives
- Institut de Recerca Contra la Leucemia Josep Carreras, Hospital Germans Trias i PujolUniversitat Autònoma de Barcelona, Institut Català d'Oncologia, Hospital Germans Trias i Pujol Barcelona Spain
| | - Isabel Granada
- Institut de Recerca Contra la Leucemia Josep Carreras, Hospital Germans Trias i PujolUniversitat Autònoma de Barcelona, Institut Català d'Oncologia, Hospital Germans Trias i Pujol Barcelona Spain
| | | | | | | | - Ramon Guàrdia
- Institut Català d'OncologiaHospital Josep Trueta Girona Spain
| | - Josep Nomdedeu
- Institut de Recerca contra la Leucemia Josep CarrerasHospital Sant Pau Barcelona Spain
| | - Marta Pratcorona
- Institut de Recerca contra la Leucemia Josep CarrerasHospital Sant Pau Barcelona Spain
| | - Mar Tormo
- Hematology Department, Hospital Clínico Valencia Spain
| | | | - Jesús‐María Hernández‐Rivas
- Hospital Universitario de SalamancaUniversidad de Salamanca, IBMCC (CSIC/USAL), IBSAL and CIBERONC Salamanca Spain
| | - Juana Ciudad
- Hospital Universitario de SalamancaUniversidad de Salamanca, IBMCC (CSIC/USAL), IBSAL and CIBERONC Salamanca Spain
| | - Alberto Orfao
- Hospital Universitario de SalamancaUniversidad de Salamanca, IBMCC (CSIC/USAL), IBSAL and CIBERONC Salamanca Spain
| | | | - Pere Barba
- Hematology Department, Hospital Vall d'Hebron Barcelona Spain
| | - Lourdes Escoda
- Institut Català d'OncologiaHospital Joan XXIII Tarragona Spain
| | - Jordi Esteve
- Institut de Recerca contra la Leucemia Josep CarrerasHospital Clínic Barcelona Spain
| | - Eulàlia Genescà
- Institut de Recerca Contra la Leucemia Josep Carreras, Hospital Germans Trias i PujolUniversitat Autònoma de Barcelona, Institut Català d'Oncologia, Hospital Germans Trias i Pujol Barcelona Spain
| | - Francesc Solé
- Institut de Recerca Contra la Leucemia Josep Carreras, Hospital Germans Trias i PujolUniversitat Autònoma de Barcelona, Institut Català d'Oncologia, Hospital Germans Trias i Pujol Barcelona Spain
| | - Evarist Feliu
- Institut de Recerca Contra la Leucemia Josep Carreras, Hospital Germans Trias i PujolUniversitat Autònoma de Barcelona, Institut Català d'Oncologia, Hospital Germans Trias i Pujol Barcelona Spain
| | - Josep‐Maria Ribera
- Institut de Recerca Contra la Leucemia Josep Carreras, Hospital Germans Trias i PujolUniversitat Autònoma de Barcelona, Institut Català d'Oncologia, Hospital Germans Trias i Pujol Barcelona Spain
| | | | | |
Collapse
|
4
|
Ribera J, García O, Moreno M, Barba P, García‐Cadenas I, Mercadal S, Montesinos P, Barrios M, González‐Campos J, Martínez‐Carballeira D, Gil C, Ribera J, Vives S, Novo A, Cervera M, Serrano J, Lavilla E, Abella E, Tormo M, Amigo M, Artola M, Genescà E, Bravo P, García‐Belmonte D, García‐Guiñón A, Hernández‐Rivas J, Feliu E. Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. Cancer 2019; 125:2810-2817. [DOI: 10.1002/cncr.32156] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Revised: 03/08/2019] [Accepted: 03/18/2019] [Indexed: 01/13/2023]
Affiliation(s)
- Josep‐Maria Ribera
- Department of Clinical Hematology ICO Badalona‐Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Autonomous University of Barcelona Badalona Spain
| | - Olga García
- Department of Clinical Hematology ICO Badalona‐Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Autonomous University of Barcelona Badalona Spain
| | - María‐José Moreno
- Department of Hematology Hospital of the Virgen de la Victoria Malaga Spain
| | - Pere Barba
- Department of Hematology Vall d’Hebron University Hospital, Autonomous University of Barcelona Barcelona Spain
| | | | - Santiago Mercadal
- Department of Hematology ICO‐Hospital Duran i Reynals, L’Hospitalet de Llobregat Catalonia Spain
| | - Pau Montesinos
- Department of Hematology Le Fe University and Polytechnic Hospital Valencia Spain
| | - Manuel Barrios
- Department of Hematology Carlos Haya Hospital Malaga Spain
| | | | | | - Cristina Gil
- Department of Hematology General University Hospital of Alicante Alicante Spain
| | - Jordi Ribera
- Department of Clinical Hematology ICO Badalona‐Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Autonomous University of Barcelona Badalona Spain
| | - Susana Vives
- Department of Clinical Hematology ICO Badalona‐Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Autonomous University of Barcelona Badalona Spain
| | - Andrés Novo
- Department of Hematology Son Espases Hospital Palma de Mallorca Spain
| | - Marta Cervera
- Department of Hematology ICO‐Hospital Joan XXIII Tarragona Spain
| | | | | | - Eugenia Abella
- Department of Hematology del Mar Hospital Barcelona Spain
| | - Mar Tormo
- Department of Hematology Clinical Hospital Valencia Spain
| | - María‐Luz Amigo
- Department of Hematology Morales Meseguer University General Hospital Murcia Spain
| | | | - Eulalia Genescà
- Department of Clinical Hematology ICO Badalona‐Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Autonomous University of Barcelona Badalona Spain
| | - Pilar Bravo
- Department of Hematology Fuenlabrada University Hospital Madrid Spain
| | | | | | | | - Evarist Feliu
- Department of Clinical Hematology ICO Badalona‐Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Autonomous University of Barcelona Badalona Spain
| | | |
Collapse
|